SUZHOU, China, February 25, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers today announced that Wutian Wu, PhD, Clinical SVP for the Company, has co-authored an article published in Nature Neuroscience on the subject “Microvascular endothelial cells engulf myelin debris and promote macrophage recruitment and fibrosis after neural injury”.
The study established a previously unidentified role for microvessels and lining microvascular endothelial cells in engulfing and degrading myelin debris after spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE), a commonly used animal model of multiple sclerosis. It also found a novel pathway for myelin debris degradation through the autophagy–lysosome system. (View article at: https://doi.org/10.1038/s41593-018-0324-9)
“The publication of this journal article is an exciting development for Re-Stem and for those with spinal cord injury”, stated Benno Jiao, CEO of the Company. “Our goal is to harness the power of cellular function in order to clear debris and reduce inflammation following neural injury and potentially promote healing and regeneration. These findings will assist us in the research and development of Re-EnableTM , our proprietary cell based intervention which, coupled with surgical procedure Re-HabTM, provides a unique regenerative opportunity that has shown remarkable functional recovery.”
Professor Wu received his medical degree in Sun YatSen University of Medical Sciences, Guangdong, China in 1975 and a Master Degree in Neuroanatomy in the same institute in 1981. He was a clinician and later a teacher for medical students for more 10 years in Mainland China. Prof. Wu received his PhD degree in Neuroscience in 1991 and continued to work in Eastern Virginia Medical School till 1996. Prof. Wu joined the Department of Anatomy, Faculty of Medicine, University of Hong Kong in January 1996 and currently serves as Professor. Prof. Wu’s research is well recognized. His contributions include a total of over 100 original peer review articles with more than 2000 citations received, initiation of 14 active international and local collaborative studies, a total of 29 US and HK research grants – 23 as principal investigator and 6 as co-investigator with total of over 20 million HKD awarded, and more than 40 invited lectures and visiting professorships.
About Re-Stem Biotech Re-Stem Biotech (Re-Stem) is biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and directors, Re-Stem currently has a robust technology platform including three profitable therapies on the market and six therapies. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing and Ganzhou. To learn more about Re-Stem, please visit www.restembio.com
Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.
RE-Stem 2023 | All Rights Reserved. Design & Developed by Themesglance